AUTHORS
Naszrin Arani, MD, Hannah Goulart, MD2, Keyur Patel, PhD, MBBS3, Mark J. Routbort, MD, PhD4, Courtney DiNardo, MD, MSCE5, Tapan Kadia I, MD6, Ghayas C. Issa, MD7, Gautam Borthakur, MD8, Nicholas Short, MD9, Musa Yilmaz, MD10, Jayastu Senapati, MBBS, MD, DM11, Sa Wang, MD12, Wei Wang, MD, PhD13, Wei Ying Jen, BM BCh, FRCPath14, Koichi Takahashi, MD,PhD15, Betul Oran, MD16, Uday Popat, MD, MBA17, Elizabeth Shpall, MD18, Naveen Pemmaraju, MD19, Elias Jabbour, MD20, Farhad Ravandi, MD21, Guillermo Garcia-Manero, MD22, Naval Daver, MD23, Sanam Loghavi, MD24
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, United States
13 The University of Texas MD Anderson Cancer Center, Houston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 The University of Texas MD Anderson Cancer Center, Houston, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background:
Targeted therapies have improved outcomes of patients (pts) with AML, but relapse remains the leading cause of mortality. UNGS-based assays detect persistent clones and impeding relapse earlier. Although FLT3 internal tandem duplication (ITD) and NPM1 mutation (mut) UNGS MRD are prognostic in first remission, their impact in R/R AML is unclear.
Methods:
We identified pts with FLT3-ITD and/or NPM1 mut R/R AML treated at MD Anderson Cancer Center who underwent UNGS MRD testing (Invivoscribe, San Diego, CA; LLOD: 5e-5) from 2024-onward. Concurrent flow cytometric (FCM) evaluation (LLOD: 1e-4), baseline demographics, disease characteristics, treatment, allogeneic stem cell transplantation (HSCT), and outcomes were collected and summarized. Kaplan-Meier analysis was used to compare survival.
Results:
48 R/R pts were included: median (med) age 63 years (range, 17-83), 26 (54%) female, and 16 ELN22 (33%) with adverse-risk disease. The cohort comprised 19 (40%) with NPM1 mut, 19 (40%) with FLT3-ITD, and 10 (21%) with both. Induction was intensive chemotherapy (IC) in 28 (58%) and lower-intensity therapy (LIT) in 20 (42%), including 18/20 (90%) venetoclax (VEN)-based. 12/29 (41%) with FLT3-ITD mut disease had received a FLT3 inhibitor (FLT3i), mostly (67%) +IC while remainder were part of a decitabine+VEN triplet, and 2 pts with NPM1 mut received menin inhibitor (MENi)-based induction. 11 (23%) had undergone HSCT, 5 (45%) in first remission.
Med prior line to salvage was 1 (range, 1-4); 30 (63%) were treated in salvage 1, 8 (17%) salvage 2, 10 (21%) salvage 3+. Med time to analyzed relapse was 25 months (mo) (IQR, 19-72). At relapse, 19 (40%) had isolated FLT3-ITD, 19 (40%) isolated NPM1 mut, and 10 (21%) both. Salvage was LIT in 39 (77%; 25 [68%] VEN-based), IC in 8 (17%), immunotherapy in 1. 25/29 (89%) pts with FLT3-ITD received a FLT3i (quizartinib, 11 [44%]; gilteritinib, 14 [56%]). 19/29 (66%) pts with NPM1 mut received MENi. Composite remission (CRc; complete remission with/without hematologic recovery, and morphologic leukemia-free state) was achieved in 34/48 (71%) R/R pts; including 10/19 (53%) with isolated FLT3-ITD, 15/19 (79%) with isolated NPM1 mut, and 9/10 (90%) both. Med cycles to best response was 2.
29/34 (85%) responders had available UNGS MRD testing at initial response assessment post salvage. All 17 with NPM1 mut were UNGS MRD+ (med VRF 485e-5, range <5 - 23261) whereas 6/13 (40%) with paired FCM were FCM+. Among 14 with FLT3-ITD, 12 (86%) were UNGS MRD+ (med VRF 39.5, range <5 - 32528) vs. 9 (64%) FCM+. 15 (44%) pts, [including 9 (60%) NPM1 mut, 3 (19%) FLT3-ITD, 3 (19%) both] ultimately achieved UNGS MRD- with continued therapy after med 17 mo (IQR 12-47 mo); including 8 (53%) after HSCT in consolidation. 13 (38%) pts received consolidative HSCT (med time to HSCT 4.7 mo), of whom 1 (7.7%) reached UNGS MRD- prior to HSCT. 12 (71%) pts who cleared UNGS MRD are alive and their disease continues to be in remission (med follow-up [F/U] 47 mo).
With med F/U of 19 mo, med relapse-free survival (RFS) and overall survival (OS) from post salvage CRc (n=34) were 10 and 25 mo, respectively. Pts (15/34, 44%) who achieved FLT3-ITD and/or NPM1 mut molecular response (UNGS MRD-) anytime during salvage had med RFS not reached (NR) vs. 6.8 mo ([95% CI 1.7-9.4], p<.0001; 1-year [yr] RFS 92% vs 0%); and OS (NR vs. 8.9 mo [4.9-NR], p=.001; 1-yr OS 85% vs 22%) vs. pts with UNGS MRD+ any level. Among pts unable to proceed to HSCT (n=21), med RFS (NR vs. 3.7 mo [1.1-1.7], p=.002) and OS (NR vs. 5.6 mo [4.9-5.6], p=.02) favored UNGS MRD- (n=6) vs. MRD+ (n=15). This remained true at 1e-4 cutoff level; RFS (NR vs. 3.9 mo [1.7-6.8], p<.0001) and OS (NR vs. 6.6 mo [4.1-8.9] p<.0001) were superior overall, including in those unable to proceed to HSCT (RFS NR vs. 3.7 mo [1.1-4.3], p=.001; OS NR vs. 5.5 mo [3.4-NR], p=.003).
7 pts who relapsed had paired UNGS MRD and FCM results 60 days before relapse; 5/7 (71%) had UNGS MRD+ vs. only 2/7 (29%) with FCM+.
Conclusion:
In R/R FLT3-ITD and/or NPM1 mut AML, UNGS MRD- during salvage (achieved in 44%) was associated with significantly superior med and 1-year RFS and OS, including in pts unable to proceed to HSCT. UNGS MRD frequently persisted at initial CRc despite FCM- highlighting higher discriminant potential. UNGS MRD may help predict impending relapse better than FCM MRD. Prospective validation should define how depth and kinetics of serial UNGS MRD can guide therapy.
DISCLOSURES
Naszrin Arani, MD: Abbvie - Honoraria; Abbvie - Consultancy (Includes expert testimony)